PHATHOM PHARMACEUTICALS INC (PHAT)
Health Care · Biotechnology · NASDAQ
Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal diseases, anchored by its potassium-competitive acid blocker platform.
What PHATHOM PHARMACEUTICALS INC does
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Its lead products are potassium-competitive acid blockers (PCABs) designed to treat acid-related disorders. The company's portfolio centers on the clinical and commercial development of vonoprazan-based therapies.
Themes: gastrointestinal health, acid-related disorders, drug commercialization
Fundamentals
- Price$7.31 as of 2026-10-20 close
- Market cap$591M as of 2026-07-27 (share count; price 2026-10-20)
- 1-year return-47.8% 2025-10-20 close $14.01 → 2026-10-20 close $7.31
- P/En/a negative earnings
- Net margin-126.3% FY2025, SEC XBRL
- Gross margin+87.1% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its interest expense implies more borrowing than the debt lines we read add up to.
- Revenue growth (YoY)+216.9% FY2025, SEC XBRL
- Beta1.05 as of 2026-09-02
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How PHAT compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross margintop 10% 189 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $74M | $59M | -$4M | -$18M | -$0.21 | -$2M† | $44000† |
| Q1 FY2026 2026-03-31 | $58M | $46M | -$15M | -$30M | -$0.37 | -$16M | $61000 |
| Q4 FY2025 2025-12-31 | $58M† | $50M† | -$6M† | -$21M† | -$0.27† | -$5M† | $87000† |
| Q3 FY2025 2025-09-30 | $50M | $43M | -$15M | -$30M | -$0.41 | -$14M† | $27000† |
| Q2 FY2025 2025-06-30 | $40M | $34M | -$60M | -$76M | -$1.05 | -$63M† | $97000† |
| Q1 FY2025 2025-03-31 | $29M | $25M | -$79M | -$94M | -$1.31 | -$85M | $18000 |
| Q4 FY2024 2024-12-31 | $30M† | $26M† | -$59M† | -$74M† | -$1.00† | -$63M† | $5000† |
| Q3 FY2024 2024-09-30 | $16M | $14M | -$71M | -$86M | -$1.32 | -$64M† | $44000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$182M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How PHATHOM PHARMACEUTICALS INC looks technically
PHATHOM PHARMACEUTICALS INC (PHAT) is trading 33.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 138 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It made a new 20-day low about 12 trading days ago. It is 60.1% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 33.7% below its 200-day average, the long-term trend line — a long-term downtrend | -33.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.10 | $8.10 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.02 | $11.02 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 8.4. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 138 trading days ago — a "death cross", a bearish long-term signal | 138 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($6.52 to $7.72) — its "stochastic" reading is 66 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 65.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $18.31 | $18.31 |
|---|---|---|
| From the 52-week high | it is 60.1% below its 52-week high (its highest price of the past year) | -60.1% |
| Above the 52-week low | it is 12.1% above its 52-week low (its lowest price of the past year) | +12.1% |
| Below the 52-week high | it is 60.1% below its highest point of the past year | 60.1% |
| Since a 20-day breakout | it made a new 20-day low about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day low about 12 trading days ago | 12 sessions |
| All-time high | its highest closing price on record is $64.54 (set on 2020-06-08) | $64.54 |
| Given back of the 52-week move | over the past year its closes ranged ($6.70 to $18.08), and it has recovered only a small part of its fall from last year’s high — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.73 to $14.10. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.4% |
| From the all-time high | it is 88.7% below its all-time high | -88.7% |
| Nearest price level | it is trading 4.7% below a resistance level at $7.66 — a price it turned at twice since 2024-12-11, most recently on 2025-07-22. Since 2024-10-21 it has 2 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.7% |
| All-time low | its lowest closing price on record is $2.21 (set on 2025-05-08) | $2.21 |
| Above the all-time low | it is 230.8% above its all-time low | +230.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4263 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4263 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.68 and $7.56 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.68 – $7.12 – $7.56 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 8.7 daily ranges below its 200-day average price (33.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.8% since the prior reading | -1.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Open gap | it gapped 23.5% below the previous close 57 sessions ago and has not traded back through the level it left behind at 11.64 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -23.5% |
| Gap filled | a 2.3% gap up opened on 2026-10-01 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +5.64% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.2 percentage points (the stock lost 2.3% while the market gained 1.0%) | -3.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 35.0 percentage points (the stock lost 31.4% while the market gained 3.6%) | -35.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 54.2 percentage points (the stock lost 45.7% while the market gained 8.5%) | -54.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 62.4 percentage points (the stock lost 47.8% while the market gained 14.6%) | -62.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 19.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -17.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $10.75 — a volume-weighted average of daily closes over 195 sessions, not a true tick-by-tick VWAP. | -32.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.20 — a volume-weighted average of daily closes over 58 sessions, not a true tick-by-tick VWAP. | -10.8% |
Price levels it has turned at before
PHAT last closed at $7.31 on 2026-10-20. Since 2024-10-21 it has turned at 2 prices below its last close and 14 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.66 | Resistance | 4.7% above the last close | turned there twice · 2024-12-11 to 2025-07-22 |
| $6.95 | Support | 4.9% below the last close | turned there four times · 2024-12-23 to 2026-09-24 |
| $8.20 | Resistance | 12.2% above the last close | turned there twice · 2025-07-07 to 2026-08-05 |
| $8.41 | Resistance | 15.1% above the last close | turned there three times · 2024-11-18 to 2026-08-20 |
| $4.47 | Support | 38.9% below the last close | turned there twice · 2025-04-29 to 2025-05-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $8.40.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $7.28 and $8.13 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $6.52.
This reading has stood for 14 trading days, since 2026-10-01.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$20.09 range $10.00 – $29.00; median $21.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PHAT
- Consensus EPS estimate$0.0346 next reporting period, as of 2026-10-18
- Estimate change, 30 days-$0.002 from $0.0366, on 2026-09-13, 35-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant accumulated deficit and ongoing history of operating losses.","High level of debt and revenue interest financing liabilities requiring significant cash flows.","Commercialization risk for new drug products in competitive gastrointestinal markets."]
What changed in the latest 10-Q
AI-assisted comparison of PHAT's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-30) references audited financial statements for year ended December 31, 2025 in opening paragraph, versus older filing (2025-10-30) which referenced year ended December 31, 2024
- Newer filing states 'future results of planned commercialization activities' in forward-looking statements section; older filing states 'future results of anticipated commercialization'
- Newer filing describes company as 'commercial-stage biopharmaceutical company' in Overview; older filing describes as 'biopharmaceutical company'
- Newer filing states 'VOQUEZNA is the only PCAB currently approved for marketing and sale in the United States' in Overview
- Newer filing specifies commercialization began 'in November 2023'; older filing provides more detailed timeline with FDA approval dates
- Newer filing reports approximately 1.35 million prescriptions filled as of April 17, 2026; older filing reported over 790,000 prescriptions as of October 17, 2025
- Newer filing states 'access for over 120 million, or over 80%, of U.S. commercial lives'; older filing states 'over 120 million, or over 80%, of total U.S. commercial lives'
- Newer filing states Phase 2 EoE trial was 'initiated' in fourth quarter of 2025; older filing also states this but with slightly different wording
- Newer filing notes NCE exclusivity 'extending through May 3, 2032' for all three products; older filing references same date but with different context
- Newer filing reports cash and cash equivalents of $180.9 million as of March 31, 2026
- Newer filing includes projection of 'reach operating profitability beginning in the third quarter of 2026, excluding stock-based compensation'
- Newer filing reports 41,612,032 shares of common stock and 3,859,000 pre-funded warrants sold from inception, generating net proceeds of approximately $665.3 million
- Removed:
- Older filing included detailed background on vonoprazan's development by Takeda, including 'peak net sales for Takeda of approximately $850 million' and approval history dating to Japan in 2014 - not present in newer filing
- Older filing stated 'Vonoprazan is the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years' - removed in newer filing
- Older filing included statement about supply chain disruption risk from Sandoz regarding clarithromycin tablets for VOQUEZNA TRIPLE PAK, noting it represents approximately 1% of total revenue - not present in newer filing
- Older filing detailed FDA approval dates (May 2022 for PAK approvals, November 1, 2023 for VOQUEZNA) - condensed in newer filing
- Older filing stated 'We continue to evaluate potential for commercial partnerships for vonoprazan in Europe and Canada' - newer filing states 'We may also explore the potential'
- Older filing language 'We also plan to evaluate the in-license or acquisition' - newer filing uses 'We may also explore...opportunities to in-license or acquire'
- Reworded:
- Newer: 'commercial-stage' vs Older: no stage descriptor (Overview opening)
- Newer: 'PCABs are a novel class of molecules that block acid secretion' vs Older: 'PCABs are a novel class of medicines that block acid secretion'
- Newer: 'The U.S. Food and Drug Administration, or FDA, approved VOQUEZNA for the relief of heartburn associated with Non-Erosive GERD, the largest category of GERD, in July 2024' vs Older: more detailed timeline with September 2023 NDA submission date included
- Newer: 'Vonoprazan was originally developed by Takeda' vs Older: 'Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan'
- Newer: 'We licensed U.S., European and Canadian rights to vonoprazan from Takeda in 2019' vs Older: 'In May 2019, we in-licensed the U.S., European, and Canadian rights'
- Newer: 'we generated increased revenues from sales of our VOQUEZNA products compared to same period in the prior year' vs Older: no comparable statement in the truncated section
- Newer: 'most prescriptions written for GERD indications' vs Older: no comparable statement
- Newer: 'we are also selectively pursuing life-cycle management opportunities' vs Older: 'we continue to evaluate potential for commercial partnerships...as well as potential development of vonoprazan into other indications'
- Newer: 'we believe that our existing cash and cash equivalents together with our anticipated product revenues, are sufficient to fund operations for at least the next twelve months' vs Older: no comparable forward cash projection statement in excerpt
- Notes:
- Older filing text is truncated at the end; final sentence on supply disruption is incomplete, limiting full comparison of that section
- Newer filing text also appears truncated at very end ('Our operating plans and other demands on our cash resources may chan...'), preventing complete comparison of final paragraph
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for PHAT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PHAT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,739,684
- Reported value $83,975,565
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PHAT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PHAT had 10,109,151 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
PHAT had 12.5% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.36 days to cover at the same settlement.
- Reported short interest (shares) 10,109,151
- Short interest (% of shares outstanding) 12.5%
- Prior settlement (shares) 10,157,209
- Reported change -0.47%
- Days to cover (reported) 7.36
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Takeda Pharmaceutical (TAK)
- AstraZeneca (AZN)
- Ironwood Pharmaceuticals (IRWD)
- Sebela Pharmaceuticals
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PHAT vs…
PHAT ranks in…
Frequently asked questions
What does PHATHOM PHARMACEUTICALS INC (PHAT) do?
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Its lead products are potassium-competitive acid blockers (PCABs) designed to treat acid-related disorders. The company's portfolio centers on the clinical and commercial development of vonoprazan-based therapies.
What sector is PHATHOM PHARMACEUTICALS INC (PHAT) in?
PHATHOM PHARMACEUTICALS INC (PHAT) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are PHATHOM PHARMACEUTICALS INC's (PHAT) competitors?
Notable peers of PHATHOM PHARMACEUTICALS INC (PHAT) include Takeda Pharmaceutical, AstraZeneca, Ironwood Pharmaceuticals and Sebela Pharmaceuticals. This peer set is informational only — not financial advice.
Is PHATHOM PHARMACEUTICALS INC (PHAT) overbought or oversold right now?
PHATHOM PHARMACEUTICALS INC (PHAT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PHAT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.